AUTHOR INDEX*

Abrams, K., 267
Alvarez, R.J., 323
Ashley, E., 395
Ashley, E.A., 55

Baumgart, D., 217
Binkley, P.F., 323
Borzak, S., 121
Burke, A.P., 349

Chew, D.P., 195
Cleland, J.G.F., 275
Coats, A.J.S., 231
Cowie, M.R., 293

Eastaugh, J., 243
Egermayer, P., 69
Eichhorn, E.J., 251
Erbel, R., 217

Farb, A., 349
Farmer, J.A., 415
Follath, F., 207
Freemantle, N., 243
Froelicher, V., 55, 395

Gheorghiade, M., 251
Goldschmidt, P.J., 323
Goldstein, J.A., 449
Gotto, A.M., Jr., 415
Grayburn, P.A., 33

Haude, M., 217
Hersh, E., 45
Heusch, G., 217
Hobbs, F.D.R., 243

Januzzi, J.L., 369

Kaul, S., 1
Kerensky, R.A., 339
Kolodgie, F.D., 349

Lanza, G.M., 13
Leopold, J.A., 381
Lindner, J.R., 111
Lopes, N., 323
Loscalzo, J., 381

Matsunaga, T.O., 45
Mayer, S., 33
McCreery, T., 45
Mendez, G.F., 293
Monroe, V.S., 339
Mukherjee, D., 479
Muller, J.E., 369
Muntwyler, J., 207

O'Neill, W.W., 455

Parilak, L.D., 339
Porter, T.R., 101

Raff, G.L., 455
Raj, S.R., 169
Raxwal, V., 55
Roffi, M., 195
Ruberg, F.L., 381

Safian, R.D., 437
Schulz, R., 217
Servoss, S.J., 369
Shah, P.K., 357
Sheldon, R.S., 169
Shetler, K., 395
Silva, J.A., 429
Slavik, R.S., 121

Tisdale, J.E., 121
Topol, E.J., 195, 479

Unger, E.C., 45
Urdahl, H., 243

Vannan, M., 45
Vasudevan, S.S., 323
Virmani, R., 349

Wei, K., 81
White, C.J., 429
Wickline, S.A., 13
Willenheimer, R., 153, 155
Willerson, J.T., 469
Woods, K.L., 267

Xie, F., 101

SUBJECT INDEX*

ABCA1 (ATP-binding cassette transporter 1), 488
ABCD trial (Appropriate Blood Pressure Control in Diabetes), 211
Abciximab
  NSTEMI clinical trials, 199–200
  pharmacology of, 196–197
  pretreatment for coronary stenting, 388
ACE (angiotensin-converting enzyme), 488–489
ACE inhibitors. *See* Angiotensin converting enzyme inhibitors
Acoustically reflective liposomes, nongaseous, 20–22
ACS. *See* Acute coronary syndromes
Acuspheres, 38
Acute coronary syndromes (ACS). *See also specific syndromes*
  future treatment directions, 390–391
  inflammation development and, 470–471
  interventional therapy. *See* Percutaneous coronary intervention
  pharmacotherapy, 377, 387–390
  plaque and, 339–340
  prevalence, 349
  prevention, 377
  serum markers, 443

*July/August (2001), pp. 1-80; September/October (2001), pp. 81-152; November/December (2001), pp. 153-230; January/February (2002), pp. 231-322; March/April (2002), pp. 323-414; May/June (2002), 415-510.

Acute coronary syndromes (ACS). *See also specific syndromes* (*Continued*)
thrombogenesis, 353, 357, 381
triggers
anger, 375
cocaine/marijuana exposure, 376
general theory for, 369–371
heavy physical exertion, 374–375
mental stress, 375
modulation of, 377
particulate air pollution, 376–377
sexual activity, 375–376
Aerosomes (MRX-115), 17–18, 38–39
AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Study), 419
AFO150 (Imagent), 40
Age, cardiovascular mortality/morbidity trials and, 156–157
Air Force/Texas Coronary Atherosclerosis Study (AFCAPS/TexCAPS), 419
Albumnex, 39
Aldosterone antagonist diuretics, interaction with digoxin, 261
Amiloride with hydrochlorothiazide, for hypertension, 210
Amiodarone, for atrial fibrillation conversion
intravenous, 132–135, 137
oral, 136, 137–139
AMIOVIRT, 179
Anger, as acute coronary syndrome trigger, 375
Angina
chronic, aspirin for, 283
stable, plaque morphology in, 351
unstable. *See* Unstable angina
Angiogenesis, with coronary microembolization, 220
Angiography. *See* Coronary angiography
Angioplasty, for STEMI, 456–457
Angioscopy, for plaque imaging, 423, 424, 443
Angiotensin converting enzyme inhibitors (ACE inhibitors)
clinical effects, 234
efficacy, clinical trial *vs.* real life, 165
interaction with aspirin, 284–287
monitoring, brain natriuretic peptide for, 310–311
vs. calcium channel blockers for hypertension, 210
Angiotensin receptor blockers. *See also specific angiotensin blockers*
ancillary properties, 233–234
clinical effects, 234–237
effects on morbidity/mortality, 237–240
pharmacodynamic effects, 232–233
Angiotensin-converting enzyme (ACE), 488–489
Animal models of atherosclerosis, inflammation and, 475–476
Anthracycline cardiotoxicity diagnosis, brain natriuretic peptide for, 305–306
Anti-arrythmic effect, of Mg^{2+} infusion in myocardial infarction, 271
Anti-atherosclerotic effects, of angiotensin receptor blockers, 237
Anti-platelet action, of Mg^{2+} infusion in myocardial infarction, 271
Antiarrhythmic agents. *See also specific antiarrhythmic agents*
class IA
adverse reactions, 145
for atrial fibrillation conversion, 124–127
class IC
adverse reactions, 145
for atrial fibrillation conversion, 127–129
class III
adverse reactions, 145–146
for atrial fibrillation conversion, 129–142
Antiarrhythmics Versus Implantable Defibrillator Trial. *See* AVID trial
Anticoagulation therapy. *See also specific anticoagulants*
for acute coronary syndromes, 388–389
for calf vein thrombosis, 72–73
for deep vein thrombosis, 74
for portal vein thrombosis, 72–73
long-term follow-up, 73–74
monotherapy *vs.* combined, 75–76
Antihypertensive drugs. *See also specific antihypertensive drugs*
clinical trials, surrogate endpoints and, 208–209
Antiplatelet drugs. *See also specific antiplatelet drugs*
for acute coronary syndromes, 387–388
with PCI, for ST-elevation myocardial infarction, 460–461
Antithrombin therapy with PCI, for ST-elevation myocardial infarction, 461–462
Apolipoprotein ϵ4, 486–487
Appropriate Blood Pressure Control in Diabetes trial (ABCD), 211
Aptamers, as ultrasonic contrast agent target, 17
ARIC (Atherosclerosis Risk in Communities), 418
Arrhythmias. *See also specific types of arrhythmias*
effect of Mg^{2+} infusion in myocardial infarction, 271
Arrhythmogenic right ventricular dysplasia, ICD usage for, 182
Arterial grafts, atherosclerosis and, 442
Arterial injury, saphenous vein graft atherosclerosis and, 438–439
Asialoglycoproteins, as ultrasonic contrast agent target, 16
Aspirin
after coronary artery bypass surgery, 281
anti-platelet effects, meta-analyses of, 278–280
benefit, biological mechanisms of, 275–277
clinical mechanisms, 277–280
cost of, 287
for acute coronary syndromes, 387

Aspirin (*Continued*)
for chronic angina, 283
for deep vein thrombosis prevention, 281–282
for heart failure, 283–284
for myocardial infarction, 280, 282–283
for ST-elevation myocardial infarction with PCI, 460
for stroke, 281, 284
for transient ischemic attack, 281, 284
for unstable angina, 280–281
harm, biological mechanisms, 275–277
interaction with ACE inhibitors, 284–287
observational data sets, 287
primary prevention, 281
side effects, 287
Atherogenesis, prothrombotic phenotype and, 386–387
Atheromatous plaque. *See* Plaque
Atherosclerosis
advanced lesions, 323–325
arterial grafts and, 442
genetics/genomics of, 328–332
inflammation and, 470, 475–476
late, saphenous vein graft disease and, 441–442
plaque. *See* Plaque
process, 469–470
progression
expression genomics and, 332
vascular injury and, 429–430
treatment, future directions, 390–391
Atherosclerosis Risk in Communities (ARIC), 418
ATP-binding cassette transporter 1 (ABCA1), 488
Atrial fibrillation
digoxin for, 256–257
direct current cardioversion for, 122
pharmacologic conversion
adverse effects, 145–146
benefits of, 122
clinical trials, 142–144
disadvantages of, 122–123
limitations of review, 146
recommendations, summary of, 146–148
study methodology for, 123
with class IA antiarrhythmic agents, 124–127
with class IC antiarrhythmic agents, 127–129
with class III antiarrhythmic agents, 129–142
prevalence, 121
resting electrocardiogram, 62
spontaneous conversion, 144, 145
therapeutic goals for, 122
AVID trial (Antiarrhythmics Versus Implantable Defibrillator)
cost-effectiveness analysis data, 188–189
low-risk group, 184–185
results, 172–173
AVID trial (Antiarrhythmics Versus Implantable Defibrillator) (*Continued*)
Beta-blockers
after myocardial infarction, 248–249
concerns about, 243–244
effectiveness, newer interventions and, 245–246
extrapolating from trial evidence, 247–248
long-term effects, 244–245
selection of, 246–247
short-term effects, 244
BEST-ICD trial, 183
early research, 243
in heart failure, digoxin and, 261–262
Bezafibrate, 421–422
BiSphere, 39–40
BNP. *See* Brain natriuretic peptide
BR-1(SonoVue), 41
Brain natriuretic peptide (BNP)
clearance, 296
clinical usage, 298–312
in disease states, 296
physiologic actions, 295
plasma levels, measurement of, 296–298
receptors, 295
reference range, 298
storage, 294–295
structure, 293–294
synthesis/secretion, 293–295
Brugada syndrome, 181
Bundle branch block, 61–62

C-reactive protein (CRP)
high-sensitivity, 419–420
inflammation and, 471
CABG. *See* Coronary artery bypass graft
CABG Patch Trial (Coronary Artery Bypass Graft Patch Trial), 178–179
CAD. *See* Coronary artery disease
CADILLAC trial, 460–461
Calcification, coronary
as risk factor, 353–355
nodules, 350, 362–363
Calcium channel blockers. *See also specific calcium channel blockers*
for hypertension, 207–208
clinical endpoints of trials, 209–211
gender and, 212
in elderly, 212
surrogate endpoints of trials, 208–209
vs. other antihypertensives, 210–214
vs. placebo, 209–210
with diabetes, 211–212
with heart failure, 212
pharmacology of, 208

Calcium channel blockers. *See also specific calcium channel blockers (Continued)*
Calf vein thrombosis, anticoagulant therapy for, 72–73
CAM. *See* Cell adhesion molecules
Canadian Implantable Defibrillator Study (CIDS)
  cost-effectiveness analysis data, 189
  results, 173–174
  score, 183–184
Candesartan, exercise tolerance and, 235–236
Captopril, 165, 254
Captopril-Digoxin Multicenter Trial, 254
CAPTURE trial, 199, 202–204
Cardiac Arrest Study Hamburg (CASH), 174–175
Cardiac marker changes, glycoprotein IIb/IIIa inhibitor clinical trials and, 202–203
Cardiogenic shock, in STEMI, percutaneous coronary intervention for, 460
Cardiovascular disease. *See also specific cardiovascular diseases*
  gene polymorphisms in, 479–480
  pharmacogenomics in
    disease-based, 483–485
    gene-based, 485–490
CARE (Cholesterol and Recurrent Events), 419, 432–433, 474
CASH (Cardiac Arrest Study Hamburg), 174–175
CASS (Coronary Artery Surgery Study), 343–344
CAT gene, 51–52
Cavitation
  microbubbles and, 46
  microvascular permeability and, 47–48
  transvascular passage of macromolecules and, 48–49
Cell adhesion molecules (CAM)
  ICAM-1 targeted liposomes, 21, 112–114
  in endothelium, 382–383
  inflammation and, 471
Censoring, 404–405
CHARM program, 239
Chlorthalidone, for hypertension, 211
Cholesterol
  fatal plaques and, 353
  high-density lipoprotein, 353, 486
  low-density lipoprotein, 474–475
  reduction, inflammation and, 474–475
Cholesterol and Recurrent Events (CARE), 419, 432–433, 474
Cholesterol ester transfer protein (CETP), 486
CIDS. *See* Canadian Implantable Defibrillator Study
Clinical trials. *See also specific clinical trials*
  design, 165–166
  early termination of, 160–162
  efficacy vs. real life efficacy, 164–165
  experimental design, 267
  for secondary prevention of sudden cardiac death, 170–175
Clinical trials. *See also specific clinical trials (Continued)*
  implementing results into clinical practice, problem with, 159–160
  interventions established by, 156
  lack of conclusiveness, reasons for, 156–159
  order of investigated drugs, 162–164
  publication bias, 165
  results extrapolation of, 163–164
  statistical significance, 155–156
Clopidogrel (Plavix), 387–388
Coagulation cascade, 384–385
Cocaine, as acute coronary syndrome trigger, 376
Concomitant therapy changes, for cardiovascular mortality/morbidity trials, 158
CONSENSUS-II (Cooperative New Scandinavian Enalapril Survival Study), 303, 308
Contrast agents, ultrasonic
  gas and shell compositions, 4
  historical aspects, 33
  microbubbles as. *See* Microbubbles
  targeted. *See* Targeted ultrasonic contrast agents
  transpulmonary
    clinical aspects, 38–41
    future directions, 41
    ideal characteristics for, 33–38
Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS-II), 303, 308
Coronary angiography
  in predicting plaque vulnerability, 339–340
  limitations of, 339
  of multifocal plaque instability, 451–452
  of plaque instability, 442
  patterns, in vulnerable plaque, 340–343
Coronary artery
  blood flow
    cyclic variations, 222
    in response to microembolization, 219–222
    with potential microembolization, 225
  microembolization. *See* Microembolization, coronary
  plaque. *See* Plaque
  vasodilation, after Mg^{2+} infusion in myocardial infarction, 271
Coronary artery bypass graft (CABG)
  aspirin after, 281, 284
  future strategies, 444
  natural history, unstable plaque and, 440–442
Coronary Artery Bypass Graft Patch Trial (CABG Patch Trial), 178–179
Coronary artery disease (CAD)
  angiographic lesion morphology, 341–345
  clinical risk prediction, 395–396
  diagnostic tests. *See* Diagnostic tests
  digoxin safety/efficacy for, 259–260
  genetics/genomics of, 328–332

Coronary artery disease (CAD) (*Continued*)
management, score-directed strategy for, 402–403
premature, 328
pretest probability, 399
prognosis, statistical techniques for, 404–405
progression, 343–345
serum markers, 443
Coronary artery stenosis
detection and quantification of severity using MBF reserve, 89–90
myocardial blood flow and, 81–82
severity, vessel remodeling and, 359–360
Coronary Artery Surgery Study (CASS), 343–344
Coronary artery thrombosis
in acute coronary syndromes, 357, 440
plaque rupture as substrate for, 357
triggering, 371
without plaque rupture, 362–363
Coronary microcirculation, myocardial contrast echocardiography, 2
CYP enzyme family, 481
Cytokines, inflammation and, 233–234

DCC (direct current cardioversion), 122
Deep vein thrombosis (DVT)
anticoagulant therapy for, 72–73
controlled prospective studies, 74
long-term follow-up, 73–74
prevention, aspirin for, 281–282
Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), 182
Definity (DMP), 40
Diabetes mellitus
glycoprotein IIB/IIIa inhibitor clinical trials and, 201–202
with hypertension, calcium channel blockers for, 211–212
Diagnostic tests
evaluation of, 396
exercise electrocardiogram. *See* Exercise stress test
pretest probability and, 399
statistical techniques, 396–399
Digitalis Investigation Group trial (DIG), 255–256, 259
Digoxin
dosage, in chronic heart failure, 258–259
electrophysiological effects, 253
for atrial fibrillation, 256–257
for chronic systolic heart failure, 254–256
for heart failure, with preserved systolic function, 262
hemodynamic effects, 252
historical aspects, 251
in chronic heart failure, remaining questions, 258–262
indications, 262
Digoxin (*Continued*)
interaction with aldosterone antagonist diuretics, 261
intoxication, 257–258
mechanism of action, 251–252
neuroendocrine effects, 252–253
nonpotassium sparing diuretics and, 260
pharmacokinetics, 254
serum concentration, 257
Dilated cardiomyopathy, with syncope, exclusion from ICD clinical trials, 180–181
DIMT (Dutch Ibopamine Multicenter Trial), 255
DINAMIT (Defibrillator in Acute Myocardial Infarction Trial), 182
Direct current cardioversion (DCC), 122
Disopyramide, for atrial fibrillation conversion, 124–126
Diuretics. *See also specific diuretics*
for hypertension, 210–211
nonpotassium sparing, digoxin and, 260
DMP (Definity), 40
Dofetilide, for atrial fibrillation conversion, 141–142
Drugs. *See also specific drugs*
efficacy, clinical trial vs. real life, 164–165
entrapment by microbubbles, 46–47
Duke Treadmill score, 406, 409
Dutch Ibopamine Multicenter Trial (DIMT), 255
Dutch Study, 171–172, 188
DVT. *See* Deep vein thrombosis
Dyslipidemia, hypercoagulability in, 421

EBCT (electron-beam computed tomography), 443
ECG. *See* Electrocardiogram
Echocardiography, myocardial. *See* Myocardial contrast echocardiography
EDRF (endothelium-derived relaxation factor), 432
Ejection fraction, implantable cardioverter-defibrillator impact and, 183
Elderly
hypertension, calcium channel blockers for, 212
predicting CAD prognosis in, 410
Electrocardiogram (ECG)
changes, glycoprotein IIB/IIIa inhibitor clinical trials and, 202–203
resting
as heart disease screen, 55–64
atrial fibrillation, 62
bundle branch block, 61–62
of left ventricular hypertrophy, 58–60
Q waves on, 60
sensitivity/specificity estimates, 62–63
ST segment abnormalities on, 61
Electrocardiogram, exercise. *See* Exercise stress test
Electron-beam computed tomography (EBCT), 443
ELITE trial, 238

ELITE-II trial, 165, 237–239
Emulsion nanoparticles
  multimodality imaging with, 25–28
  perfluorocarbon, 22–25
Endothelial adhesion molecules, targeted, 112–113
Endothelium
  abnormalities, plaque vulnerability and, 416–418
  dysfunction, atherogenesis and, 386–387
  normal function, 381–385
    hemostatic balance and, 384–385
    surface protein expression and, 381–384
Endothelium-derived relaxation factor (EDRF), 432
Endpoints, 404–405
Eptifibatide
  for NSTEMI clinical trials, 198
  pharmacology of, 196–197
ESSENCE study, 464
Exclusion criteria, for cardiovascular mortality/morbidity trials, 157
Exercise stress test
  enhancing accuracy of, 396
  right-sided chest leads and, 404
  scores
    "simplified" derivation of, 401–402
    comparing with physicians, 410–411
    consensus of, 401
    in CAD management strategy, 402–403
    prognostic, 405–410
    ST/HR index in, 403–404
    validated, 400–401
    variables in, 399–400
Exercise tolerance, angiotensin receptor blockers and, 235–237

FACET (Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial), 211–212
Factor VII, 487–488
Familial hypercholesterolemia, 328
Fas-ligand, 327
FGF (fibroblast growth factor), 51
Fibrinogen, as cardiovascular risk factor, 421
Fibroatheroma, thin cap, 350
Fibroblast growth factor (FGF), 51
Fibrous-cap thickness, plaque vulnerability and, 359
Flecainide, for atrial fibrillation conversion, 127–128
Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET), 211–212
Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease II Trial (FRISC II), 462
Framingham Offspring Study, 421
FS069 (Optison), 40–41

Gender
  calcium channel blockers for with hypertension and, 212
Gender (*Continued*)
  cardiovascular mortality/morbidity trials and, 157
  glycoprotein IIB/IIIa inhibitor clinical trials and, 201
Gene polymorphisms. *See* Polymorphisms
Gene therapy
  barriers to gene delivery, 48
  for vascular disease, 45–46
  targeted ultrasonic contrast agents for, 49–52
  with vascular endothelial growth factor, 45
GISSI-1 trial, 460
Global Utilization of Strategies to Open Occluded Coronary Arteries (GUSTO-4), 195, 199–200, 202, 388
Glycoprotein IIb/IIIa inhibitors
  clinical trials
    biologic/statistical considerations, 200–201
    for acute coronary syndromes, 388
    for NSTEMI, 197–201
    subgroups and, 201–204
  cost-effectiveness, 204
  pharmacology of, 196–197
Glycoprotein IIb/IIIa receptor antagonists
  with PCI, for ST-elevation myocardial infarction, 460–461
Glycoprotein IIb/IIIa receptor, in platelet aggregation, 196
GUSTO-4 (Global Utilization of Strategies to Open Occluded Coronary Arteries), 195, 199–200, 202, 388

HDL (high-density lipoprotein), 353, 486
Heart failure
  diagnosis, brain natriuretic peptide for, 298–299
  prognosis, brain natriuretic peptide for, 306–310
  repetitive coronary microembolization model, 220–221
  treatment
    aspirin for, 283–284
    by plasma BNP increase, 312
    digoxin for, 254–255, 258–262
    monitoring, brain natriuretic peptide for, 310–311
    tailoring by neurohormonal profiling, 311–312
Heart rate recovery, in prognostic scores, 406, 408
Hemostatic balance, of endothelium, 384–385
Heparin
  for deep vein thrombosis, 72–73
  low-molecular weight, for acute coronary syndromes, 388–389
  thrombus dissolution
    administration route and, 70–71
    animal and in vitro studies, 70
    clinical studies, 71–72
    dosage levels and, 70–71
  thrombus propagation, unexpected prospective trial results, explanation for, 76

Heparin (*Continued*)
unfractionated
alternatives for deep vein thrombosis, 74
for acute coronary syndromes, 388
with percutaneous coronary intervention
for NSTEMI with unstable angina, 464
for STEMI, 461–462
HER-2 expression, 481–482
High-density lipoprotein (HDL), 353, 486
HOT study, 278, 281
Human Genome Project, 483
Hydrochlorothiazide and amiloride, for hypertension, 210
Hypertension
β-blockers for, 210–211
calcium channel blockers for, 207–211
diuretics for, 210–211
pharmacogenomics, 483–485
with diabetes, calcium channel blockers for, 211–212
with heart failure, calcium channel blockers FOR, 212
Hypertrophic cardiomyopathy, ICD usage for, 181–182
Hypothesis testing, inadequate for cardiovascular mortality/morbidity trials, 159

Ibutilide, for atrial fibrillation conversion, 139–141
ICAM-1 targeted liposomes, 21, 112–114
ICD. *See* Implantable cardioverter-defibrillator
IDNT trial, 239–240
Imagent (AFO150), 40
ImaRx Corporation, microbubbles-based technology, 17–18, 49–51
Implantable cardioverter-defibrillator (ICD)
benefit, persistence of, 185–186
clinical trials
competing modes of death and, 179–180
cost-effectiveness analysis data, 188–189
exclusion criteria, 180–181
for primary SCD prevention, 175–179
for secondary SCD prevention, 170–175
unresolved issues, 179, 180
cost implications, 189–190
cost-effectiveness analysis, 187–188
development/evolution of, 169–170
extending benefits of, 182–183
for rare hereditary ventricular arrhythmias, 181–182
implantation guidelines, 170
quality of life and, 186–187
response prediction, 183–185
Infarct-artery patency, 457–459
Inflammation
atherosclerosis and, 470, 475–476
cytokines and, 233–234
development of acute coronary syndromes and, 470–471

Inflammation (*Continued*)
local, unstable atherosclerotic plaques and, 472–474
molecular mediators of, 111–112
plaque, 358
cellularity and, 418–420
disruption and, 431
systemic markers of, 471–472
treatment of, 474–475
ultrasound assessment of
acoustic properties of phagocytosed microbubbles, 117–119
future directions, 119–120
microbubble-leukocyte interactions and, 114–117
targeting endothelial adhesion molecules for, 112–114
with coronary microembolization, 220
INSIGHT (Intervention as a Goal in Hypertension Treatment), 210
Integrins, in endothelium, 382–383
International Study of Infarct Survival (ISIS), 243
International Study of Infarct Survival-4 (ISIS-4), 269
Intervention as a Goal in Hypertension Treatment (INSIGHT), 210
Interventions, established by clinical trial, 156
Intravascular thermography, for plaque imaging, 423, 424
Intravascular ultrasound, for plaque imaging, 423, 424, 443
Ischemia-reperfusion injury, myocardial protection against, 271–272
ISIS (International Study of Infarct Survival), 243
ISIS-4 (International Study of Infarct Survival-4), 269

Lamifiban, for non-ST segment elevation myocardial infarction, clinical trials, 198–199
LDL (low-density lipoprotein), 474–475
Left bundle branch block, resting electrocardiogram, 61–62
Left ventricular dysfunction
diagnosis, brain natriuretic peptide for, 299–305
implantable cardioverter-defibrillator impact and, 183
Left ventricular hypertrophy, resting electrocardiogram of, 58–60
Leicester Intravenous Magnesium Intervention Trial-2 (LIMIT-2), 268–269
Leukocytes, interaction with microbubbles, 115–117
Levovist (SHU508), 40
LIMIT-2 (Leicester Intravenous Magnesium Intervention Trial-2), 268–269
Linear oscillations, 5
Lipid core, plaque vulnerability and, 326, 358
Lipid-lowering therapy, 432–433
Liposomes, nongaseous acoustically reflective, 20–22
Long Beach VA score, 405–406

Long QT syndrome, 181, 485
Loop diuretics, digoxin and, 260
Losartan
  anti-atherosclerotic effects, 237
  efficacy, clinical trial *vs.* real life, 165
  exercise tolerance and, 235–237
  pharmacodynamic effects, 232–233
  ventricular remodeling and, 234–235
Low-density lipoprotein (LDL), 474–475
Low-molecular weight heparin, for acute coronary syndromes, 388–389
Low-risk patient selection, for cardiovascular mortality/morbidity trials, 157–158

Macrophage activation, in atherosclerosis progression, 332
MADIT trial, 176–178, 188
MADIT II trial, 182
Magnesium therapy, for myocardial infarction
  empirical evidence from trials, 268–269
  mechanistic evidence, 271–272
  meta-analysis of trials, 269–271
  timing in relation to coronary reperfusion, 272–273
Magnetic resonance imaging (MRI), 443
Mallinckrodt Corporation, microbubble-based technology, 18–19
Marijuana, as acute coronary syndrome trigger, 376
Matrix degrading metalloproteinase gene polymorphisms, 329
Matrix degrading metalloproteinases (MMPs), 361
MBF. *See* Myocardial blood flow
Mechanical index (MI), 5
Medical informatics, 483
Medical therapy, adjunctive for with PCI, 460–462, 464
Mental stress, as acute coronary syndrome trigger, 375
MI (mechanical index), 5
MI-DAS (Multicenter Isradipine Diuretic Atherosclerosis Study), 210–211
Microarray DNA chip technology, 483
Microbubbles
  acoustic properties, 36–37
  cavitation and, 46
  clinical applications, 111
  concentration, video intensity and, 82–83
  destruction, 37–38
  diameter of, 34
  drug entrapment, 46–47
  for gene therapy, 46–52
  for myocardial contrast echocardiography, 2–4
  for targeted gene therapy, studies on, 49–52
  for ultrasound-induced thrombus dissolution
    effectiveness of, 104–105
    in vivo studies of, 105–106
  gas core of, 34–35
Microbubbles (*Continued*)
  interaction with leukocytes, 115–117
  liposome-based, 17–18
  nonlinear oscillations of, 5–10
  perfluorocarbon exposed sonicated dextrose albumin, 19–20
  perfluorocarbon-containing, for acute arterial thromboses in humans, 106–108
  phagocytosed, acoustic properties of, 117–119
  pharmacokinetics of, 84–85
  protein-encapsulated, 18–19
  shell, 35
  surface characteristics, 35–36
  tissue contrast enhancement, determination of, 83
Microembolization, coronary
  clinical evidence for, 222–227
  evidence from postmortem histologic studies, 217–218
  experimental pathophysiology of, 218–222
  protection devices, 225–227
  remaining questions, 227
Microthrombi, in acute coronary syndromes, 353
MILIS (Multicenter Investigation of Limitation of Infarct Size), 374–375
Milrinone, 258–259
Milrinone Multicenter Trial, 254–255
MIOS (Myocardial Infarction Onset Study), 374–375
MIRACL (Myocardial Ischemia Reeducation with Aggressive Cholesterol Lowering), 390, 417–418
MMP gene polymorphisms, 329
MMPs (matrix degrading metalloproteinases), 361
Monoclonal antibody and fragments, as ultrasonic contrast agent target, 15–16
Mortality
  clinical trials. *See* Clinical trials
  surrogate endpoints for, 164
MRI (magnetic resonance imaging), 443
MRX-115 (aerosomes), 17–18, 38–39
Multicenter Investigation of Limitation of Infarct Size (MILIS), 374–375
Multicenter Isradipine Diuretic Atherosclerosis Study (MI-DAS), 210–211
Multicenter Unsustained Tachycardia Trial (MUSTT), 179
Muscle cells, direct injection for gene therapy, 48
MUSTT (Multicenter Unsustained Tachycardia Trial), 179
Myocardial blood flow (MBF)
  absolute, quantification of, 89
  coronary artery stenosis and, 81–82
  quantification by myocardial contrast echocardiography, 85–87
  transmural distribution, 94–96
Myocardial contrast echocardiography

absolute myocardial blood flow quantification, 89
advantages of, 1
clinical applications, 1
coronary artery disease detection methods, 94–98
image processing and tissue contrast enhancement determination, 83
microbubbles and, 2–4
myocardial blood flow quantification, 85–87
of coronary microcirculation, 2
physiologic principles of, 4–10
reversible perfusion defect, mechanism of, 90–94
stenosis severity and detection using MBF reserve, 89–90
video intensity
microbubble concentration and, 82–83
phasic changes in, 96–98
Myocardial infarction
aspirin after, 280, 282–283
beta-blockers usage after. *See* Beta-blockers, after myocardial infarction
familial premature, 329
magnesium therapy
empirical evidence from trials, 268–269
mechanistic evidence, 271–272
meta-analysis of trials, 269–271
non-ST-elevation. *See* Non-ST elevation myocardial infarction
onset, cyclic variation of, 371–374
pathophysiology, of morning onset, 372–373
plaque morphology in, 351–352
ST-elevation. *See* ST-elevation myocardial infarction
triggers, nocturnal, 373–374
Myocardial Infarction Onset Study (MIOS), 374–375
Myocardial Ischemia Reeducation with Aggressive Cholesterol Lowering (MIRACL), 390, 417–418
Myocardial salvage, 457–459

N-Acetyltransferases (NATs), 480
Natriuretic peptide receptors, 295
NC100100 (Sonazoid), 41
Neovascularity, plaque vulnerability and, 359
Nifedipine, vs. hydrochlorothiazide and amiloride for hypertension, 210
Non-ST elevation myocardial infarction (NSTEMI)
Abciximab clinical trials, 199–200
angiographic lesion morphology, 344–345
medical management, 195
with unstable angina
adjunctive medication for, 464
stent therapy for, 463
Nonlinear oscillations, of microbubbles, 5–10
Nordic Diltiazem study (NORDIL), 210
Nordic Study, of ICD efficacy, 183
NT-proBNP
clearance, 296
plasma levels, measurement of, 296–298
reference range, 298
Nuclear scintigraphy, for plaque instability evaluation, 443

Optison (FS069), 40–41

P-selectin, 489
PACT trial, 461–462
PAI (plasminogen activator inhibitor), 422
PAMI trials (Primary Angioplasty in Myocardial Infarction), 457–458, 461
PARAGON. *See* Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in Global Organization Network
Particulate air pollution, as acute coronary syndrome trigger, 376–377
PCI. *See* Percutaneous coronary intervention
Peak negative pressure, 5
Peptides, as ultrasonic contrast agent target, 16
Percutaneous coronary intervention (PCI)
facilitated, for ST-elevation myocardial infarction, 461–462
for ST-elevation myocardial infarction, 455–462
rapid risk assessment for, 455–456
with unstable angina, 462–464
risk assessment, 462–463
Perfluorocarbon emulsion nanoparticles
development of, 22–25
multimodality imaging with, 25–28
Perfluorocarbon exposed sonicated dextrose albumin microbubbles (PESDA), 19–20, 106–108
Peripheral vessels. *See also* Saphenous vein
bypass grafts, atherosclerosis in, 430–431
multifocal plaque instability in, 452–453
saphenous arteries, 437–438
PESDA (perfluorocarbon exposed sonicated dextrose albumin microbubbles), 19–20, 106–108
Phage display techniques, 16
Pharmacogenetics
benefits, 492–493
economic considerations, 490–492
ethical considerations, 492
future directions, 493
vs. pharmacogenomics, 480
Pharmacogenomics
in cardiovascular disease, 483–490
vs. pharmacogenetics, 480
Pharmacotherapy. *See specific drugs*
Physical activity
heavy exertion, as acute coronary syndrome trigger, 374–375
in preventing acute coronary syndromes, 377
Plaque

cellularity, inflammation and, 418–420
clinical manifestations of, 340–341
components of, 326, 430
destabilization, thrombosis and, 387
development, 386–387
erosion
in coronary thrombosis, 362–363
morphology of, 350
platelet activation and, 421
fatal, risk factors associated with, 353
inflammation, 358
instability, 444–445
invasive evaluation of, 442–443
noninvasive evaluation of, 443
lipid core, 326, 358
local pro-coagulant activity, 420–422
matrix and lipid pool composition, 420
mature, 430
morphology
in angina, 351
in myocardial infarction, 351–352
in sudden coronary death, 352–353
multifocal instability, 449
angiographic evidence of, 451–452
clinical implications, 453
in peripheral vessels, 452–453
pathologic evidence of, 450–451
rupture, 440
acute coronary syndrome triggering and, 369–371
as coronary thrombosis substrate, 357
causes of, 370–371
consequences of, 362
experimental models of, 361–362
gene expression and, 332
genetics/genomics of, 328–332
inflammation and, 431
matrix dysregulation hypothesis, 360–364
morphology of, 349–350
pathophysiology of, 325–328
thrombosis and, 359
triggers of, 362
vasoconstriction and, 431–432
stabilization, 363–364
vulnerable/unstable, 430–431, 440
coronary angiography patterns in, 340–343
coronary artery bypass graft natural history and, 440–442
detection of, 422–425
determinants of, 416–422
histologic features of, 415–416
lipid core and, 326, 358
local inflammation and, 472–474
pathology of, 349–355
prediction of, 339
Plaque-stabilizing agents, for acute coronary syndromes, 389–390
Plasminogen activator inhibitor (PAI), 422
Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in Global Organization Network (PARAGON)
A trial, 198–200, 202
B trial, 198, 202–203
Platelet PL^{A2} polymorphisms, 485–486
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM), 197–198, 200–204
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS), 198, 200–204
Platelets
activation, plaque erosion and, 421
aggregation, atherosclerosis progression and, 429–430
coronary microembolization and, 220
gene polymorphisms, 329–330
physiology/biology of, 196
Plavix (clopidogrel), 387–388
Polymorphisms
clinical recognition of, 480–482
clinical relevance/implications of, 490
in cardiovascular disease, 479–480
platelet PL^{A2}, 485–486
single nucleotide, 482–463
Polysaccharides, as ultrasonic contrast agent target, 16
Portal vein thrombosis, anticoagulant therapy, 72–73
Postphlebitic syndrome
incidence, 73–74
literature review, 69–70
Pravastatin
clinical trials, 419–420
endothelial function and, 417
Pravastatin Inflammation/CRP Evaluation (PRINCE), 419–420
Primary Angioplasty in Myocardial Infarction trials (PAMI), 457–458, 461
PRINCE (Pravastatin Inflammation/CRP Evaluation), 419–420
PRISM (Platelet Receptor Inhibition in Ischemic Syndrome Management), 197–198, 200–204
PRISM PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms), 198, 200–204
Procainamide, for atrial fibrillation conversion, 126–127
PROMISE (Prospective Randomized Milrinone Survival Evaluation), 258–259
Propafenone, for atrial fibrillation conversion, 128–129
Prospective Randomized Milrinone Survival Evaluation (PROMISE), 258–259
Prospective Randomized Study of Ventricular Failure and Efficacy of Digoxin (PROVED), 255, 259, 260
Proteomics, 481–482
PROVED (Prospective Randomized Study of Ventricular Failure and Efficacy of Digoxin), 255, 259, 260

Pulmonary artery thrombosis, after pulmonary embolism, 74–75
Pulmonary embolism
  risk, 72
  thrombus propagation after, in pulmonary artery, 74–75
PURSUIT trial, 198, 201–202

Q waves, on resting electrocardiogram, 60
Quality of life, implantable cardioverter-defibrillator and, 186–187
Quinidine, for atrial fibrillation conversion, 124–126

RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme), 255, 259, 260
RALES trial, 261
Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme (RADIANCE), 255, 259, 260
RENAAL, 240
Renal impairment, glycoprotein IIB/IIIa inhibitor clinical trials and, 202
Right bundle branch block, 61–62
ROC curves, 397–399

Saphenous arteries, 437–438
Saphenous vein
  injury, atherosclerosis and, 439
  structure/function, 437–438
Saphenous vein graft occlusive disease, 441–444
SCD-HeFT[69], 182
Screening tests. *See also specific screening tests*
  resting electrocardiogram as, 55–64
  value of, 56
Sexual activity, as acute coronary syndrome trigger, 375–376
SHOCK trial, 460
SHU508 (Levovist), 40
Single nucleotide polymorphisms (SNPs), 482–463
Sonazoid (NC100100), 41
SonoVue (BR-1), 41
Sotalol, for atrial fibrillation conversion, 129, 131–132
SPEED trial, 461–462
ST segment abnormalities
  on resting electrocardiogram, 61
  resting depression, predicting prognosis in, 409
ST-elevation myocardial infarction (STEMI)
  angiographic lesion morphology, 344–345
  angioplasty, vs. thrombolytic therapy, 456–457
  percutaneous coronary intervention
    after failed thrombolysis, 459
    cardiogenic shock and, 460
    immediate after successful thrombolysis, 459–460
    infarct-artery patency, 457–459
ST-elevation myocardial infarction (STEMI) (*Continued*)
    mortality rates, 457–459
    myocardial salvage and, 457
    rapid risk assessment for, 455–456
    stent therapy, 459
    ventricular function, 457–459
    with adjunctive medical therapy, 460–462
  percutaneous coronary intervention for, 455–462
  with unstable angina, percutaneous coronary intervention for, 462–464
Statins. *See also specific statin drugs*
  alteration of platelet aggregation, 421
  endothelial function and, 417
  for acute coronary syndromes, 389–390
  plasminogen activator inhibitor levels and, 422
Statistical significance
  definition of, 155–156
  early termination of clinical trials and, 160–162
Statistical techniques
  for coronary artery disease prognosis, 404–405
  for diagnostic tests, 396–399
STEMI. *See* ST-elevation myocardial infarction
Stent therapy
  for NSTEMI with unstable angina, 463
  for ST-elevation myocardial infarction, 459
STOP (Swedish Trial in Old Patients with Hypertension), 210
Stroke, aspirin for, 281, 284
Sudden cardiac death
  ICD usage for, 181
  plaque morphology in, 352–353
  prevalence, 169
  primary prevention, ICD trials for, 175–179
  secondary prevention, ICD trials for, 171–175
Swedish Trial in Old Patients with Hypertension (STOP), 210
Syncope with DCM, exclusion from ICD clinical trials, 180–181
SYST-EUR study, 211

TACTICS (Treat Angina With Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy), 198, 202, 203
Tangier disease, 328–329
Targeted ultrasonic contrast agents
  clinical applications, 13
  for endothelial adhesion molecules, 112–114
  for gene therapy, 46, 49–52
  ideal properties of, 13–14
  microbubbles-based, 17–20
  nonmicrobubble-based, 20–25
  potential ligands, 15–17
  targeting mechanism, 14–15
Thiazide diuretics, digoxin and, 260
Thienopyridine derivatives, with PCI for STEMI, 461
Thiopurine methyltransferase (TPMT), 481

Thromboemboli, source/consequences, 222–225
Thrombolysis, 385
Thrombolysis in Myocardial Infarction (TIMI)
  first trial, 198, 202, 203
  IIIb trial, 462
  second trial, 374–375
  third trial, 458, 461
Thrombolytic therapy. *See also specific thrombolytic agents*
  failed, for ST-elevation myocardial infarction, PCI for, 459
  for acute coronary syndromes, 389
  successful, for ST-elevation myocardial infarction, immediate PCI for, 459–460
  vs. angioplasty, for ST-elevation myocardial infarction, 456–457
Thrombomodulin, 488
Thrombosis. *See also* Coronary artery thrombosis; Deep vein thrombosis
  angiographic detection of, 342–343
  endothelium-derived factors and, 385–386
  initiation, 384–385
  plaque destabilization and, 387
  plaque rupture and, 359
  propagation, literature review, 69–70
  pulmonary artery, after pulmonary embolism, 74–75
Thrombospondin, 489–490
Thrombus dissolution. *See also* Thrombolytic therapy
  anticoagulants for, 72–73
  heparin effects on. *See* Heparin, thrombus dissolution
  ultrasound-induced
    alone, effectiveness of, 102–103
    historical aspects, 101
    rationale for, 101–102
    with microbubbles, 104–105
    with perfluorocarbon-containing microbubbles, 106–108
TIA (transient ischemic attack), 281, 284
TIMI. *See* Thrombolysis in Myocardial Infarction
Tirofiban
  NSTMI clinical trials, 197–198
  pharmacology of, 196–197
Tissue factor pathway inhibitor, 422
TPMT (thiopurine methyltransferase), 481
Transient ischemic attack (TIA), 281, 284
Transpulmonary contrast agents, ideal characteristics for, 33–38
Treat Angina With Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS), 198, 202, 203
Troponin, glycoprotein IIB/IIIa inhibitor clinical trials and, 202–203
Ultrafast computerized tomography, for plaque imaging, 423, 425
Ultrasound systems. *See also* Myocardial contrast echocardiography
  contrast agents. *See* Contrast agents, ultrasonic; Targeted ultrasonic contrast agents
  for thrombus dissolution
    historical aspects, 101
    rationale for, 101–102
  physiologic principles of, 4–10
Unstable angina
  angiographic lesion morphology, 344–345
  aspirin for, 280–281
  coronary microembolization model of, 221–222
  plaque morphology in, 351
  with non-ST elevation myocardial infarction
    adjunctive medication for, 464
    stent therapy for, 463
  with ST-elevation myocardial infarction, PCI for, 462–464

V.HeFT-II trial, 234
VA-HIT, 422
VAL-Heft, 239
Valsartan, 233
VANQWISH (Veterans Affairs Non-Q-Wave Intervention Strategies in Hospital), 462
Vascular endothelial growth factor (VEGF), 45
Vascular injury, atherosclerosis progression and, 429–430
Vascular magnetic resonance imaging, for plaque imaging, 423, 425
Vasoconstriction, plaque disruption and, 431–432
Vasodilation, after Mg^{2+} infusion in myocardial infarction, 271
VEGF (vascular endothelial growth factor), 45
Ventricular arrhythmias, rare hereditary, 181–182
Ventricular function, 457–459
Ventricular remodeling, angiotensin receptor blockers and, 180, 234–235
Ventricular tachycardia, exclusion, from ICD clinical trials, 180
Verapamil, for hypertension, 211
Veterans Affairs Non-Q-Wave Intervention Strategies in Hospital (VANQWISH), 462

Warfarin
  for acute coronary syndromes, 389 for deep vein thrombosis, 72–73
WASH study, 283–284
Women, predicting CAD prognosis in, 408–409